Cardiogenic Shock

This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page

News | Cardiogenic Shock

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

Home September 22, 2022
Home
News | Cardiogenic Shock

September 19, 2022 —  Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...

Home September 19, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Cardiogenic Shock

June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...

Home June 01, 2022
Home
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Feature | Cardiogenic Shock

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

Home May 12, 2022
Home
News | Pharmaceuticals

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

Home March 31, 2022
Home
News | Cardiogenic Shock

March 22, 2022 –  Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to ...

Home March 22, 2022
Home
Videos | Cardiogenic Shock

Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy ...

Home November 16, 2021
Home
The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.
Feature | Cardiogenic Shock | By Dave Fornell, Editor

April 29, 2021 — The results of a large, national heart attack study show that patients with  cardiogenic shock survived ...

Home April 29, 2021
Home
Videos | Cardiogenic Shock

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

Home April 28, 2021
Home
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one ...

Home October 26, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
Subscribe Now